A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital

Kannan, G; Anitha, R.; Rani, Vanitha; Palani, Thennarasu; Alosh, J; Vasantha, J; Martin, Jovita; Monga, Uma

doi:10.4103/0022-3859.85207

Cited by 33 publications

(34 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although, depending on the study center, these statistics were different, for example, in the study by Guastaldi et al., 17 the major interactions accounted for 14.1% of the total interactions. On the other hand, in our study, about 44.4% of detected DDIs are in the moderate category, which was approximately equal to another similar study, 18 and about 40.6% of DDIs classified as major. Some studies have also reported higher percentages, for example, Richelmann et al.…”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East

Moghaddas

Adib-Majlesi

Sabzghabaee

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Patients suffering from solid tumors use a wide range of cytotoxic drugs. In this study, we aimed to detect, document, and descriptively analyze the potential drug–drug interactions in hospitalized solid tumor’s patients in a Middle Eastern referral oncology–hematology University-affiliated hospital. Materials and methods In this cross-sectional study, the medical record of solid tumor’s patients who were admitted to the referral oncological center in Isfahan, Iran, during the six months period (2018) were considered. We included all patients who had received at least two chemotherapy or nonchemotherapy drugs simultaneously. The potential drug–drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver.1.1 online software. Results During the study period, a total of 141 cancer patients were recruited, and their drug therapy regiment was thoroughly analyzed. We detected 227 drug–drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively. One hundred and fourteen patients (80.8%) encountered at least one potential drug–drug interactions during their hospitalization. Mechanistically, most of drug–drug interactions (56.4%) were pharmacodynamics. Interaction between granisetron and metoclopramide were the top 10 detected interaction (11.4%). The interaction between docetaxel and carboplatin was the most frequent drug–drug interactions between oncology drugs (2.6% of total drug–drug interactions). Conclusion Potentially moderate or major drug–drug interactions frequently occur among solid tumor’s cancer patients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern.

show abstract

Section: Discussionsupporting

confidence: 68%

“…1 The prevalence of potential drug interactions in adult oncology centers in 2009 6 was estimated to be between 12% and 63%, and this prevalence has been reported in some adult oncology centers at even higher ranges, ranging from 36% to 60%. 17,18…”

Section: Discussionmentioning

confidence: 99%

Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East

Moghaddas

Adib-Majlesi

Sabzghabaee

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In the present study drug-drug interactions were observed to be 167 out of which 20% was major, 78% was moderate and 1% was minor, this does not differs greatly from the study carried out by Kannan et al,which projects reporting of 213 interactions out of which 9% was major, 56% was moderate and 33% minor respectively [22]. Further in the present study, among chemotherapeutic drugs, it was found that methotrexate was the most potentially interacting drug followed by cisplatin and doxorubicin.…”

Section: Discussionmentioning

confidence: 31%

To Study the Therapeutic Management, Drug Related Problems and Concomitant Use of Drugsin Patients With Cancer

Pramila

Abraham

Pawar

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To study the prescribing patterns of chemotherapeutic drugs, concomitant drugs and to determine the drug-related problems in cancer patients. Methods:A prospective and retrospective observational study was conducted over a period of 6 mo in a tertiary care teaching hospital, Pune after ethical approval and informed consent. Patients were then interviewed for patient information like demographics, treatment, and associated drug related problems using specially designed proforma and then required data was introduced in Microsoft excel spreadsheets. Results:Out of 60 patients 50 were enrolled in this study during which 9 different sites of cancer were examined. The maximum number of patients with cancer resides in the age group of 51-60 y (32%) and more common in females in 27 (54%). The most prevalent risk factor and co-morbidity encountered were tobacco chewing 13 (26%) and hypertension 8 (16%), respectively. On the further evaluation of data, the findings suggested that the majority of patients were prescribed with an alkylating group of anti-neoplastic agents, paclitaxel+platinum-based compound regimen, and the drug paclitaxel. On screening, 167 drug interactions were observed, of these most of the interactions were in the moderate category. The most common organ system affected was gastrointestinal system 135 (30.80%) whereas the prevalent toxicity was hyperuricemia. Polypharmacy was not observed, whereas antacid (ranitidine) was frequently prescribed during hospitalisation and discharge. Conclusion:This study has highlighted certain facts and drawbacks in medication-related care which can be addressed by conducting future studies in cancer care in order to provide patient-specific outcomes.

show abstract

“…[ 7 8 16 ] One study from South India has reported drug–drug interactions involving anticancer drugs but does not mention the error rate of the prescriptions studied. [ 17 ] However, in our study, all the drugs were given parenterally as part of a protocol and there were no clinically relevant drug interactions in any of the prescriptions.…”

Section: Discussionmentioning

confidence: 97%

Prescription errors in cancer chemotherapy:Omissions supersede potentially harmful errors

Mathaiyan

Jain

Dubashi

et al. 2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Objective:To estimate the frequency and type of prescription errors in patients receiving cancer chemotherapy.Settings and Design:We conducted a cross-sectional study at the day care unit of the Regional Cancer Centre (RCC) of a tertiary care hospital in South India.Materials and Methods:All prescriptions written during July to September 2013 for patients attending the out-patient department of the RCC to be treated at the day care center were included in this study. The prescriptions were analyzed for omission of standard information, usage of brand names, abbreviations and legibility. The errors were further classified into potentially harmful ones and not harmful based on the likelihood of resulting in harm to the patient. Descriptive analysis was performed to estimate the frequency of prescription errors and expressed as total number of errors and percentage.Results:A total of 4253 prescribing errors were found in 1500 prescriptions (283.5%), of which 47.1% were due to omissions like name, age and diagnosis and 22.5% were due to usage of brand names. Abbreviations of pre-medications and anticancer drugs accounted for 29.2% of the errors. Potentially harmful errors that were likely to result in serious consequences to the patient were estimated to be 11.7%.Conclusions:Most of the errors intercepted in our study are due to a high patient load and inattention of the prescribers to omissions in prescription. Redesigning prescription forms and sensitizing prescribers to the importance of writing prescriptions without errors may help in reducing errors to a large extent.

show abstract

A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital

Abstract: Though there was not any life threatening interactions, the potential interactions were brought to the oncologist purview for ensuring patients safety and to avoid undesirable effects.

Cited by 33 publications

References 18 publications

Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East

Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East

To Study the Therapeutic Management, Drug Related Problems and Concomitant Use of Drugsin Patients With Cancer

Prescription errors in cancer chemotherapy:Omissions supersede potentially harmful errors

Contact Info

Product

Resources

About